Skip Ribbon Commands
Skip to main content

Dr Lim Wei Wen

Dr Lim Wei Wen

BSc (Hons), PhD


Dr Lim Wei Wen graduated with a Bachelor of Biomedical Sciences with double majors in Physiology and Microbiology & Immunology, and further completed his bachelor degree with 1st class Honours in Physiology at the University of Adelaide. He completed his PhD dissertation on cardiac remodelling in mouse models of hypertrophic cardiomyopathy and diabesity from the University of Adelaide, South Australia. He returned to Singapore to join Prof Stuart Cook’s research team at the National Heart Centre Singapore as a Research Fellow in 2016. He currently holds joint appointment as a Research Fellow with the Programme in Cardiovascular & Metabolic Disorders at Duke-NUS Medical School. At National Heart Research Institute Singapore (NHRIS), he studies the role of novel factors in cardiac defects and vascular disorders in preclinical models of disease, employing cell and molecular biology and applied physiology. In collaboration with researchers from the Duke-NUS Medical School, he is currently researching on new therapeutic targets in cardiovascular and metabolic disorders.


• PhD in Medicine, University of Adelaide, Australia, Mar 2011 to April 2016. 
• BSc. (Hons) in Physiology, University of Adelaide, Australia, Jan 2010 to Dec 2010. 
• BSc. in Biomedical Science, University of Adelaide, Australia, July 2008 to Dec 2009. 
• Dip. in Biomedical Science (Biomedical Technology), Temasek Polytechnic, Singapore, Jan 2003 to Dec 2005.

Professional Appointments and Committee Memberships

• Research Fellow, National Heart Research Institute Singapore, National Heart Centre Singapore, 2016-present 
• Research Fellow, Programme in Cardiovascular & Metabolic Disorders, Duke-NUS Medical School, 2017-present 
• Microbiologist, National Heart Centre Singapore Institutional Biosafety Committee (NHCS IBC), 2018-current 
• External member, Temasek Polytechnic Institutional Review Board (TP-IRB), 2019-present 
• Alternate member, SingHealth Experimental Medicine Centre Advisory Committee, 2020-2022


• International Society for Heart Research (Australasian Section) Postdoctoral Publication Prize for Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models, 2020

Research Interests

• Vascular biology 
• Cardiac arrhythmias 
• Fibrosis 
• Inflammation 
• Metabolic syndrome

Publications and Research Trials

• IL-11 is a crucial determinant of cardiovascular fibrosis. Schafer S, Viswanathan S, Widjaja AA, Lim WW, Moreno-Moral A, DeLaughter DM, Ng B, Patone G, Chow K, Khin E, Tan J, Chotani SP, Ye L, Rackham OJL, Ko NSJ, Sahib NE, Pua CJ, Tee NGZ, Xie C, Wang M, Maayz H, Lim S, Saar K, Blachut S, Petretto E, Schmidt S, Putoczki T, Guimares-Camboa N, Wakimoto H, van Heesch S, Sigmundsson K, Lim SL, Soon JL, Chao VTT, Chua YL, Tan TE, Evans SM, Loh YJ, Jamal MH, Ong KK, Chua KC, Ong BH, Chakaramakkil MJ, Seidman JG, Seidman CE, Hubner N, Sin KYK, Cook SA. Nature. 2017 Nov 13;552(7683):110-115. 
• Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models. Lim WW, Corden B, Ng B, Vanezis K, D’Agostino G, Widjaja AA, Song WH, Xie C, Su L, Kwek XY, Tee NGZ, Dong J, Ko NSJ, Wang M, Pua CJ, Jamal MH, Soh B, Viswanathan S, Schafer S, Cook SA. Sci Rep. 2020 Oct 20;10:17853. 
• Therapeutic targeting of interleukin-11 signalling reduces pressure overload–induced cardiac fibrosis in mice. Corden B*, Lim WW*, Song W, Chen X, Ko NSJ, Su L, Tee NGZ, Adami E, Schafer S, Cook SA. J Cardiovasc Transl Res. 2021 Jun 26;14(2):222-228. *Joint first author 
• Antibody-mediated neutralization of IL11 signalling reduces ERK activation and cardiac fibrosis in a mouse model of severe pressure overload. Lim WW, Corden B, Ye L, Viswanathan S, Widjaja AA, Xie C, Su L, Tee NGZ, Schafer S, Cook SA. Clin Exp Pharmacol Physiol. 2021 Apr;48(4):605-613. 
• Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Ng B, Dong J, D’Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, Xie C, Pua CJ, Chacko AM, Guimarães-Camboa N, Evans SM, Byrne AJ, Maher TM, Liang J, Jiang D, Noble PW, Schafer S, Cook SA. Sci. Transl. Med. 2019 Sep 25;11(5):eaaw1237. 
• Electrophysiological and Structural Remodeling of the Atria in a Mouse Model of Troponin-I mutation linked Hypertrophic Cardiomyopathy: Implications for Atrial Fibrillation. Lim WW, Neo M, Thanigaimani S, Kuklik P, Ganesan AN, Lau DH, Tsoutsman T, Kalman JM, Semsarian C, Saint DA, Sanders P. Int J Mol Sci. 2021 Jun 28;22(13):6941. 
• Slowed atrial and atrioventricular conduction and depressed HRV in a murine model of hypertrophic cardiomyopathy. Lim WW, Baumert M, Neo M, Kuklik P, Ganesan AN, Lau DH, Tsoutsman T, Semsarian C, Sanders P, Saint DA. Clin Exp Pharmacol Physiol. 2016 Jan;43:95-101. 
• Simultaneous conduction mapping and intracellular membrane potential measurement of action potential parameters in isolated atria. Neo M, Morris D, Kuklik P, Lau D, Dimitri H, Lim WW, Sanders P, Saint DA. Can J Physiol Pharmacol. 2016 May; 94(5):563-569. 
• Bipolar Electrogram Shannon Entropy at Sites of Rotational Activation Implications for Ablation of Atrial Fibrillation. Ganesan AN, Kuklik P, Lau DH, Brooks AG, Baumert M, Lim WW, Thanigaimani S, Nayyer S, Mahajan R, Kalman JM, Roberts-Thomson KC, Sanders P. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):48-57.

Research Trials

  • Updated on